Global Botulinum Toxin Industry

LONDON, Feb. 9, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 15 companies including many key and niche players such as -

Allergan Plc

Ipsen Group

Medy-Tox Inc.

Merz Pharma GmbH & Co. KGaA

Metabiologics, Inc.

Download the full report: https://www.reportbuyer.com/product/119494/

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Cosmetic Applications..............I-3 Therapeutic Applications..............I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Botulinum Toxin: Expanding Cosmetic & Therapeutic Applications to Propel Growth.............. II-1 Developed Regions Dominate Botulinum Toxin Market II-2 Developing Markets to Drive Future Growth II-3 Table 1: Healthcare Spending as % of GDP by Geographic Region (2016E) (includes corresponding Graph/Chart) II-4 Table 2: Top Countries with the Highest Per Capita Healthcare Spending (2014) (includes corresponding Graph/Chart) II-5 Cosmetic BTX - A Promising Application Market II-5 Factors Propelling the Cosmetic BT Market - In a Nut Shell II-6 Rise in the Number of Musculoskeletal Indications - An Opportunity Indicator..............II-7 Pharma Companies Keenly Eye Lucrative BT Market II-8

2. COMPETITIVE LANDSCAPE..............II-9 Allergan Leads the Global BTX Market II-9 Table 3: Leading Brands in the Global Botulinum Toxin Market (2015): Percentage Breakdown of Sales for Botox, BTX-A, Dysport, Meditoxin and Xeomin (includes corresponding Graph/Chart).............. II-9 Botulinum Toxin Products Worldwide II-10 Botox - The Leading Brand in Cosmetic BTX Market II-10 Biosimilar BTX Variants Challenge Botox's Leadership II-10 Discontinuation of PurTox Averts Competition to Botox® II-11 Lack of Differentiation among Approved BTX Products II-11 Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin by Safety and Efficacy..............II-12 Revance Therapeutics: All Hopes on Topical Botox Formulation II-12 Daewoong Pharmaceutical All Set to Make a Mark on the International Scenario..............II-12 A Review of Major BTX Products II-13 Comparison of Botox®, Dysport® and Xeomin® by Indications and Year of Approval..............II-13 BOTOX®.............. II-14 Approvals and Indications of Botox in Select Regions II-15 Key Characteristics of Botox® and Botox® Cosmetic II-15 Common Adverse Reactions with Botox II-16 Therapeutics to Offer Higher Prospects for Botox II-16 Botox Therapeutic Approvals in the US by Indication II-16 Migraine Indication Bolsters Allergan's Botox Sales II-17 Dysport®.............. II-17 Key Characteristics of Dysport® II-18 Ipsen Counts on New Indications for Future Growth of Dysport II-18 Dysport Therapeutic Development Pipeline by Region II-18 Dysport Cosmetic Development Pipeline by Region II-19 Next Generation Dysport - A Breakthrough in BTX Market on the Cards.............. II-19 Xeomin®.............. II-19 Key Characteristics of Xeomin® II-19 Xeomin® FDA Approval and Indications II-20 Global Expansion Helps Merz Gain in the BTX Market II-20 Myobloc®/NeuroBloc®..............II-20 Key Characteristics of Myobloc® II-21 Meditoxin®.............. II-21 PurTox®.............. II-21 Key Characteristics of PurTox® II-22 RT001.............. II-22 Revance's RT001 - Potential Revolution in BTX Market under Development.............. II-22 How Does RT001 Work?..............II-22 RT001 - A Potential Convenient Treatment Option for Hyperhydrosis Patients..............II-23 RT002.............. II-23 RT002 - Opportunities in the Therapeutics Arena II-23

3. MARKET TRENDS & ISSUES..............II-24 Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market.............. II-24 Table 4: Non-Surgical Cosmetic Procedures Worldwide (2015): Percentage Breakdown of Procedure Volume for Injectables (Botulinum Toxin, Calcium Hydroxylapatite, Hyaluronic Acid and Poly-L-Lactic Acid), Facial Rejuvenation and Others (includes corresponding Graph/Chart) II-24 Botulinum Toxin - The Preferred Solution in Facial Injectables Market..............II-25 Table 5: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2015): Percentage Breakdown of Procedure Volume by Age Group (includes corresponding Graph/Chart) II-26

Table 6: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2015): Percentage Breakdown of Procedure Volume by Gender (includes corresponding Graph/Chart) II-26 Growing Acceptance of Cosmetic BTX Treatments Favors Market Growth.............. II-26 Rising Disposable Incomes Propel Sales II-26 Table 7: Annual Disposable Incomes in US$ '000 for Select Countries (2012) (includes corresponding Graph/Chart) II-27 Longer Life Expectancy Bolsters Market Growth II-28 Table 8: Life Expectancy at Birth in Years of People in Select Countries (2015E) (includes corresponding Graph/Chart).............. II-28 Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?..............II-28 Urgent Need for Physician Education about Off-Label Usage II-29 High Voltage Ad Campaigns Boost Patient Awareness II-29 Digital Revolution to Impact Consumer Choices II-29 Financing of Non-Reimbursed Healthcare: Need of the Hour II-30 Combination Therapies: A Double Whammy Success II-30 Botulinum Toxin - Potential Applications in Treatment of Dental Diseases.............. II-31 Short-lived Aesthetic Effects: A Strong Business Case for Revision Treatments..............II-32 Undesirable Side Effects: A Challenge to Reckon With II-32 Immunogenicity Undermines Patient Compliance II-32 Reduction of Protein Load in BTX Products - The Probable Answer for Immunogenicity..............II-32 Antigenicity: A Problematic Issue in Drug Development II-33 Stringent Regulations Delay Market Approvals & Put Reimbursements in Limbo..............II-33 Non-Injectable Alternatives to Turn On the Heat II-33 Alternative Methods of Botulinum Application under Development - A Review..............II-34 Higher Product Costs to Challenge Market Growth II-34 Consumer Skepticism: The Biggest Challenge to Beat II-35 Animal Cruelty - A Part & Parcel of Botox Testing II-35 Botulinum Toxins - A Wonder Drug or Bio-terror Threat? II-35 Fears of Terrorism & Biological Warfare Thwart International Trade.............. II-36

4. PRODUCT OVERVIEW.............. II-37 Botulinum Toxin: A Poison That Cures II-37 Structure & Mechanism of Action II-37 Disadvantages.............. II-38 Classification of Botulinum Toxin II-38 Botulinum Toxin Type A..............II-38 Historical Timeline of Botulinum Toxin: 1885-2002 II-39 Botulinum Toxin Type B..............II-39 Procedure.............. II-39 Anaesthesia.............. II-39 Injection Procedure..............II-40 Applications of Botulinum Toxin..............II-40 Cosmetic Applications..............II-40 Glabellar Lines.............. II-40 Facial Wrinkles.............. II-40 Key Cosmetic Indications for Botulinum Toxin II-41 Crow's Feet.............. II-41 Forehead Rhytids..............II-41 Temporal Brow Lift..............II-41 Lower Eyelid Rhytids..............II-42 Downturned Lips.............. II-42 Pebbly Chin.............. II-42 Therapeutic Applications..............II-42 Movement Disorders/Pain..............II-42 Cervical Dystonia..............II-42 Hemifacial Spasm.............. II-43 Blepharospasm.............. II-43 Strabismus.............. II-43 Site of Injection and Doses of Neurotoxins used in the Treatment of Dystonias..............II-44 Chronic Pain.............. II-45 Botox in Migraine Treatment II-45 List of Countries where Botox has been Approved for Prophylaxis of Headache in Adults Suffering from Chronic Migraine.............. II-46 Table 9: Modes of Injection of Onabotulinum ToxinA for Chronic Migraine by Dose and Muscle Injected II-46 Hyperhidrosis.............. II-46 Bladder Dysfunctions..............II-46 Spasticity.............. II-47 Other Applications..............II-47 Side Effects.............. II-48 An Overview of Side Effects of BTX Treatment II-48 Table 10: Side-Effects of BOTOX Treatment for Urinary Incontinence Associated with Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 12 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart) II-48

Table 11: Side-Effects of BOTOX Treatment for Urinary Incontinence Associated with Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 44 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart) II-49

5. RESEARCH BREAKTHROUGHS IN THE RECENT PAST II-50 University of Kansas Researchers Study Botulinum ToxinA Role in Minimally Invasive Treatment of Neurogenic Bladder II-50 Researchers at Baylor College of Medicine Revealed Use of Botox Injections for Treatment of Filamentary Keratitis II-50 Researchers at Medical School of Hannover and Sanford-Burnham Medical Research Institute Study Effect of the Hostile Human Stomach Environment on BT..............II-51 Investigators Prove Role of BTX A for Treatment of Achalasia II-51 Researchers at University of Freiburg Conduct New Studies on Salmonella.............. II-52 Researchers at Monash University Use Botox to Resolve Asthma Wrinkles.............. II-52

6. PRODUCT INTRODUCTIONS/APPROVALS II-53 Galderma Initiates Phase II Clinical Trial on Botulinum Toxin II-53 Daewoong Unveils Nabota Botulinum Toxin-Type Formula II-53 Medy-TOX Submits Patent Application for Lyophilized Botulinum Toxin.............. II-53 Botox Receives Approval for Treatment of Ankle Disability in the UK.............. II-53 Anterios Develops AI-09 Next-Generation Injectable Botulinum Product.............. II-53 Ipsen Receives Health Canada Approval for Dysport® II-53 Eisai Announces Plans to Launch Nerbloc® in Japan II-53 Cangene Receives FDA Approval for Botulism Antitoxin II-54 Allergan Receives FDA Approval for BOTOX® for the Treatment of Crow's Feet Lines in Adults..............II-54

7. RECENT INDUSTRY ACTIVITY..............II-55 Allergan Gains Marketing Approval for BOTOX Vista® in Japan II-55 Allergan Takes Over Anterios..............II-55 FDA Approves BOTOX® for Treatment of Adult Lower Limb Spasticity II-55 Revance Releases Phase 2 Trial Results of RT001 Topical Botulinum Toxin Type A Drug Candidate II-55 Ipsen Collaborates with EpiVax for Developed Next-Gen Botulinum Toxins.............. II-55 Revance Begins Phase 3 Clinical Trial for Botulinum Toxin Type A Topical Gel.............. II-55 Revance Commences Phase 2 Study for RT002 Botulinum Toxin Type A II-56 Revance Begins Phase 2 Trial for Botulinum toxin Type A Topical Gel.............. II-56 Bloomage BioTechnology and Medytox to Establish JV in China II-56 Ipsen Gains FDA's sBLA Approval for Dysport® II-56 Actavis Bags FDA Approval for Expanding BOTOX® Label II-56 Actavis Acquires Allergan..............II-56 Ipsen and Galderma Expand Partnership II-57 Allergan Completes Licensing Agreement with Medytox II-57 Ipsen Acquires Syntaxin..............II-57 Ipsen Enters into R&D Collaboration with Harvard Medical School II-57 Galderma Commences Clinical Trials on BT-based Muscle Relaxant II-57 Anterios Conducts Phase 2b Clinical Trials on ANT-1207 Botulinum Toxin.............. II-57 Medytox Inks Technology Transfer Agreement with Allergan II-57

8. FOCUS ON SELECT GLOBAL PLAYERS..............II-58 Allergan Plc (Ireland)..............II-58 Ipsen Group (France)..............II-58 Medy-Tox Inc. (South Korea)..............II-59 Merz Pharma GmbH & Co. KGaA (Germany) II-59 Metabiologics, Inc. (US)..............II-59 Revance Therapeutics, Inc. (US)..............II-60 US WorldMeds (US).............. II-60

9. GLOBAL MARKET PERSPECTIVE..............II-61 Table 12: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-61

Table 13: World Historic Review for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart) II-62

Table 14: World 14-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-63

Table 15: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) II-64

Table 16: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-65

Table 17: World 14-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. II-66

Table 18: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) II-67

Table 19: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-68

Table 20: World 14-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. II-69

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Current and Future Analysis..............III-1 Therapeutic BTX Market - New Entrants Slow in Gaining Market Share.............. III-1 Approved Therapeutic Indications of Botulinum Toxin in the US by Year of Approval..............III-1 Neurogenic OAB - A Relatively Smaller Market Opportunity III-2 Idiopathic OAB Bodes Healthy Prospects for Botox III-2 Cosmetic BTX Market: Rapid Growth in Store III-2 Table 21: Age-wise Distribution for Botulinum Toxin Procedures Performed in the US for the Year 2015 (includes corresponding Graph/Chart)..............III-4

Table 22: Gender Distribution for Botulinum Toxin Procedures Performed in the US (2015) (includes corresponding Graph/Chart)..............III-4 Increasing Demand for Cosmetic Treatments Bodes Well for BTX Market.............. III-4 Some Interesting Facts on Cosmetic Procedures III-5 Table 23: Number of Surgical & Non-Surgical Cosmetic Procedures ('000s) in the US for the Years 1997, 2014 & 2015 (includes corresponding Graph/Chart) III-6

Table 24: Top 5 Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (In '000s) for 2015 (includes corresponding Graph/Chart) III-7

Table 25: Top 5 Non-Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed ('000s) for 2015 (includes corresponding Graph/Chart) III-7 Table 26: Total Number of Cosmetic Procedures Performed by Category in the US (2015)..............III-8 Table 27: Number of Botulinum Toxin Procedures Performed in the US (1997, 2014 & 2015) (includes corresponding Graph/Chart).............. III-9

Table 28: Average Cost of Botulinum Toxin Per Procedure in the US (2007- 2015) (includes corresponding Graph/Chart) III-9 Demand for Professional Help On Rise III-10 Aging Baby Boomers Drive Aesthetic Business III-10 Table 29: US Population by Age Group (2015 & 2030): Percentage Share Breakdown for 0-14, 15-64, and 65+ Age Groups (includes corresponding Graph/Chart) III-10

Table 30: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-11 Expanding Physician Base Extends Impetus to Growth III-11 Table 31: Average Physician/Surgeon Fees per Procedure in the US (2015).............. III-12 Competitive Landscape..............III-13 Allergan's Botox Leads Cosmetic BTX Market III-13 Major BTX Products and Associated Fillers in the Cosmetic Botulinum Toxin Market..............III-13 Table 32: Leading Brands in the US Cosmetic Neurotoxin Treatment Market (2015): Percentage Breakdown of Value Sales for Botox, Dysport and Others (includes corresponding Graph/Chart) III-13 Dysport Takes on Botox in the Therapeutic Space III-14 Table 33: Leading Brands in the US Therapeutic Botulinum Toxin Market (2013): Percentage Breakdown of Value Sales for Botox and Dysport (includes corresponding Graph/Chart) III-14 AAN Releases New Guidelines on BTX for Identified Disorders III-14 Rise in Botulinum Toxin Lawsuits - A Concern for Physicians? III-15 Product Launches/Approvals..............III-16 Strategic Corporate Developments III-16 Key Players.............. III-18 B.Market Analytics..............III-19 Table 34: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-19

Table 35: US Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-20

Table 36: US 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-21

2. CANADA.............. III-22 Market Analysis.............. III-22 Table 37: Canadian Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-22

Table 38: Canadian Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-23

Table 39: Canadian 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-24

3. JAPAN.............. III-25 A.Market Analysis.............. III-25 Current and Future Analysis..............III-25 Strategic Corporate Development III-25 B.Market Analytics..............III-26 Table 40: Japanese Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-26

Table 41: Japanese Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-27

Table 42: Japanese 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-28

4. EUROPE.............. III-29 A.Market Analysis.............. III-29 Current and Future Analysis..............III-29 BTX Cosmetic Market Positioned for Growth III-29 Botox Approvals and Indications in Select European Countries III-29 Anti-Aging Treatment on the Rise among Young Mothers III-30 Regulations for Botulinum Toxin Usage in the EU III-30 The United Kingdom..............III-30 Cosmetic Treatment Procedures in the UK III-30 Snapshots.............. III-31 Russia.............. III-32 Mandates Registration of BTX Drugs III-32 Product Approvals/Trials..............III-32 Strategic Corporate Developments III-33 Key Players.............. III-34 B.Market Analytics..............III-36 Table 43: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-36

Table 44: European Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-37

Table 45: European 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-38

5. ASIA-PACIFIC.............. III-39 A.Market Analysis.............. III-39 Current and Future Analysis..............III-39 Botox Approvals and Indications in Select Asian Countries III-39 A Peek into Select Markets..............III-39 Australia.............. III-39 China.............. III-40 Rising Demand for Cosmetic Treatments - Opportunity for BTX III-40 Botulinum Toxin Injections Approved by China Food and Drug Administration (CFDA) III-40 India - An Emerging Market for Botox III-40 South Korea.............. III-41 Botulinum Toxin Market - Cosmetic Sector to Fuel Growth III-41 Table 46: South Korean Botulinum Toxin Use by Application for the Years 2005, 2010 and 2015 (includes corresponding Graph/Chart).............. III-41 Strong Demand for Cosmetic Procedures - Potential for BTX Market.............. III-41 Table 47: Working Women as % of Total Female Population and Monthly Income of Working Women (in KRW Million) for 2005, 2010 & 2015 (includes corresponding Graph/Chart) III-42

Table 48: Aging Population in Korea (2015 & 2025): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart)..............III-42

Table 49: Foreign Patients Visiting Korea for Plastic Surgery & Dermatology Procedures as a % of Total Visits of Foreign Patients (includes corresponding Graph/Chart) III-43 Meditoxin Dominates Domestic BTX Market III-43 Table 50: Leading Brands in the South Korean Botulinum Toxin Market (2015): Percentage Breakdown of Sales for Botox, Botulax, Meditoxin, Nabota and Others (includes corresponding Graph/Chart)..............III-44

Table 51: Average Price of Botulinum Toxin Products by Brand in South Korea (2015) (In KRW per Unit) (includes corresponding Graph/Chart)..............III-44 List of Domestic Botox Products in Korea III-45 Product Launches/Approvals..............III-45 Strategic Corporate Developments III-46 Key Players.............. III-46 B.Market Analytics..............III-48 Table 52: Asia-Pacific Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-48

Table 53: Asia-Pacific Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-49

Table 54: Asia-Pacific 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-50

6. REST OF WORLD.............. III-51 A.Market Analysis.............. III-51 Current and Future Analysis..............III-51 Latin America: Facial Injectables Market Set for Strong Growth III-51 Israel: Health Ministry Bans Cosmetic Botox Treatment by Dentists.............. III-51 Botox Approvals and Indications in RoW III-52 Botox Approvals and Indications in Select Latin American Regions.............. III-52 Botox Approvals and Indications in Other Select Global Regions III-52 B.Market Analytics..............III-53 Table 55: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-53

Table 56: Rest of World Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-54

Table 57: Rest of World 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-55

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 15 (including Divisions/Subsidiaries - 18)

The United States (6) Japan (1) Europe (5) - France (1) - Germany (1) - The United Kingdom (1) - Rest of Europe (2) Asia-Pacific (Excluding Japan) (6)

Download the full report: https://www.reportbuyer.com/product/119494/

About Reportbuyer

Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

http://www.reportbuyer.com

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-botulinum-toxin-industry-300405341.html

SOURCE ReportBuyer